Ann B. Nattinger, MD, MPH
Associate Provost for Research; Senior Associate Dean for Research, School of Medicine; Professor of Medicine, Lady Riders Professor of Breast Cancer Research; Principal Investigator, CHDS
Locations
- Office of Research
MFRC #3102
Contact Information
General Interests
Biography
Ann B. Nattinger, MD, MPH, MACP, is Associate Provost for Research; Senior Associate Dean for Research, School of Medicine; Professor of Medicine, Lady Riders Professor of Breast Cancer Research; Principal Investigator, CHDS at the 星空无限传媒 in Milwaukee. Dr. Nattinger is a nationally recognized breast cancer health services researcher. She studies variations in cancer treatment and follow-up care, disparities in care by race and socioeconomic status, and cancer survivorship issues. Her work, funded mostly by the National Cancer Institute, has been published in leading journals, such as New England Journal of Medicine, Lancet, and JAMA. As Founding Director of the 星空无限传媒Center for 星空无限传媒 and Outcomes Research (now Center for Advancing Population Science), Dr. Nattinger developed a college-wide interdisciplinary group of health services and disparities researchers. Until 2016, she was Chief of General Internal Medicine. In this capacity, she developed new hospitalist and perioperative programs and led 100 faculty members. As Associate Provost since 2016, she oversees the entire portfolio of research for MCW. She has assisted 星空无限传媒in developing a comprehensive plan for research growth and innovation. In addition, she leads the research infrastructure, including all related regulatory offices. She is a Master of the American College of Physicians and has served as President of the Society of General Internal Medicine.
Publications
-
(Rademacher N, Zhou Y, McGinley EL, Laud PW, Yen TWF, Ponce SB, Nattinger AB, Beyer KMM.) Cancer Med. 2024 Jul;13(14):e7397 PMID: 39030995 PMCID: PMC11258551 SCOPUS ID: 2-s2.0-85199018217 07/20/2024
-
(Spellecy R, Thompson N, Nattinger AB.) Ann Intern Med. 2024 Mar;177(3):383-384 PMID: 38346309 SCOPUS ID: 2-s2.0-85188479399 02/12/2024
-
(Dong Y, Hanson R, Penlesky AC, Nattinger AB, Heinrich TW, Pezzin LE.) WMJ. 2023 Dec;122(5):319-324 PMID: 38180917 SCOPUS ID: 2-s2.0-85181629574 01/05/2024
-
(Penlesky AC, Dunn C, Hanson R, Lodes M, Nattinger AB, Singh S.) WMJ. 2023 Dec;122(5):346-348 PMID: 38180922 SCOPUS ID: 2-s2.0-85181632740 01/05/2024
-
(Farkas AH, Nattinger AB.) Ann Intern Med. 2023 Nov;176(11):ITC161-ITC176 PMID: 37956433 SCOPUS ID: 2-s2.0-85178498893 11/13/2023
-
(Singh S, Laud PW, Crotty BH, Nanchal RS, Hanson R, Penlesky AC, Fletcher KE, Stadler ME, Dong Y, Nattinger AB.) Am J Med Qual. 2023 Sep-Oct 01;38(5):229-237 PMID: 37678301 SCOPUS ID: 2-s2.0-85170151971 09/08/2023
-
(Nattinger AB, Bickell NA, Schymura MJ, Laud P, McGinley EL, Fergestrom N, Pezzin LE.) J Clin Oncol. 2023 Apr 10;41(11):2067-2075 PMID: 36603178 PMCID: PMC10419674 SCOPUS ID: 2-s2.0-85152169276 01/06/2023
-
(Braun EJ, Singh S, Penlesky AC, Strong EA, Holt JM, Fletcher KE, Stadler ME, Nattinger AB, Crotty BH.) BMJ Qual Saf. 2022 Oct;31(10):716-724 PMID: 35428684 SCOPUS ID: 2-s2.0-85128972108 04/17/2022
-
(Sanchez AM, Busse K, MacKinnon K, Henk L, MacKinnon GE, Brown J, Mauermann S, Dobrowski T, Jungmann J, Bultman J, Singh S, Nattinger AB.) WMJ. 2021 Dec;120(4):305-308 PMID: 35025179 SCOPUS ID: 2-s2.0-85123461368 01/14/2022
-
(Rivera F, Gmehlin CG, Pezzin LE, Hanson R, Perez A, Singh S, Ledeboer NA, Buchan BW, Nattinger AB, Munoz-Price LS.) WMJ. 2021 Dec;120(4):301-304 PMID: 35025178 SCOPUS ID: 2-s2.0-85123460891 01/14/2022
-
(Rivera F, Munoz-Price LS, Nattinger AB.) J Gen Intern Med. 2021 Oct;36(10):3238 PMID: 34378114 PMCID: PMC8354303 08/12/2021
-
(Goodwin JS, Li S, Hommel E, Nattinger AB, Kuo YF, Raji M.) JAMA Netw Open. 2021 Aug 02;4(8):e2120622 PMID: 34383060 PMCID: PMC9026593 08/13/2021